| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
|
J Natl Cancer Inst
|
2006
|
14.60
|
|
2
|
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
|
J Clin Oncol
|
2007
|
8.65
|
|
3
|
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
|
J Natl Cancer Inst
|
2006
|
8.38
|
|
4
|
A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data.
|
Genome Biol
|
2010
|
2.72
|
|
5
|
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
|
Clin Cancer Res
|
2008
|
2.56
|
|
6
|
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
|
Clin Cancer Res
|
2008
|
2.16
|
|
7
|
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis.
|
Breast Cancer Res
|
2008
|
2.06
|
|
8
|
Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies.
|
Proteomics
|
2005
|
1.69
|
|
9
|
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
|
Clin Cancer Res
|
2003
|
1.55
|
|
10
|
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
|
Clin Cancer Res
|
2012
|
1.42
|
|
11
|
HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
|
PLoS One
|
2008
|
1.31
|
|
12
|
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.
|
Clin Cancer Res
|
2002
|
1.23
|
|
13
|
Nintendo Wii video-gaming ability predicts laparoscopic skill.
|
Surg Endosc
|
2010
|
1.23
|
|
14
|
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
|
Cancer Res
|
2009
|
1.20
|
|
15
|
Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer.
|
Cancer Res
|
2006
|
1.12
|
|
16
|
Appendiceal faecaliths are associated with right iliac fossa pain.
|
Ann R Coll Surg Engl
|
2010
|
1.12
|
|
17
|
Necrosis and hypoxia in invasive breast carcinoma.
|
Breast Cancer Res Treat
|
2003
|
1.12
|
|
18
|
Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer.
|
Oncogene
|
2005
|
1.11
|
|
19
|
Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus.
|
J Pathol
|
2004
|
1.06
|
|
20
|
Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF.
|
Am J Pathol
|
2010
|
1.02
|
|
21
|
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
|
Cancer Immunol Immunother
|
2009
|
0.99
|
|
22
|
Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients.
|
Int J Cancer
|
2006
|
0.97
|
|
23
|
Notch regulation of tumor angiogenesis.
|
Future Oncol
|
2011
|
0.93
|
|
24
|
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.
|
Breast Cancer Res
|
2012
|
0.89
|
|
25
|
Acute cholecystits leading to ischemic ECG changes in a patient with no underlying cardiac disease.
|
JSLS
|
2011
|
0.86
|
|
26
|
An investigation of factors supporting the psychological health of staff in a UK emergency department.
|
Emerg Med J
|
2011
|
0.83
|
|
27
|
Exploring the impact of expertise, clinical history, and visual search on electrocardiogram interpretation.
|
Med Decis Making
|
2013
|
0.83
|
|
28
|
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
|
Breast Cancer Res Treat
|
2010
|
0.82
|
|
29
|
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.
|
Clin Cancer Res
|
2009
|
0.82
|
|
30
|
Laparoscopic approach to appendectomy reduces the incidence of short- and long-term post-operative bowel obstruction: systematic review and pooled analysis.
|
J Gastrointest Surg
|
2014
|
0.81
|
|
31
|
The role of psychological symptoms and social group memberships in the development of post-traumatic stress after traumatic injury.
|
Br J Health Psychol
|
2012
|
0.79
|
|
32
|
Neurogenic and psychogenic acute postconcussion symptoms can be identified after mild traumatic brain injury.
|
J Head Trauma Rehabil
|
2013
|
0.77
|
|
33
|
Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.
|
Biochim Biophys Acta
|
2004
|
0.77
|
|
34
|
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
|
Cancer Chemother Pharmacol
|
2013
|
0.77
|
|
35
|
Automated uro-oncology data collection: the Cancer Research Uro-Oncology Database.
|
BJU Int
|
2009
|
0.76
|
|
36
|
Spousal relationship satisfaction following acquired brain injury: the role of insight and socio-emotional skill.
|
Neuropsychol Rehabil
|
2007
|
0.76
|
|
37
|
JMY protein, a regulator of P53 and cytoplasmic actin filaments, is expressed in normal and neoplastic tissues.
|
Virchows Arch
|
2014
|
0.76
|
|
38
|
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
|
Br J Clin Pharmacol
|
2003
|
0.76
|
|
39
|
Hinchingbrooke Hospital's reply to "inadequate" rating on patient care.
|
BMJ
|
2015
|
0.75
|
|
40
|
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'.
|
Breast Cancer Res Treat
|
2005
|
0.75
|